Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining experimental and computational tools to unravel copper-based metallodrug interactions with proteins

  • Peña Aparicio, Joaquim|||0000-0001-6477-8127
  • Zapirain Gysling, Iker|||0000-0001-5117-7082
  • Simaan, A. Jalila|||0000-0003-2537-0422
  • Capdevila, Mercè|||0000-0002-2246-0994
  • Iranzo, Olga|||0000-0001-8542-2429
  • Palacios, Òscar|||0000-0002-2987-7303
  • Maréchal, Jean-Didier|||0000-0002-8344-9043
  • Bayón, Pau|||0000-0002-3064-8866
Metallodrugs are widely used in the treatment of several diseases, including cancer. Many bloodstream proteins exhibit high affinities for metals and metal-based compounds, and these interactions have been shown to impact metallodrug pharmacokinetics and pharmacodynamics, ultimately influencing their therapeutic performance. Several spectroscopic, spectrometric, and computational techniques have been used to further understand drug-protein binding modes at the molecular level over the last few years. However, there is still plenty of room to ascertain the full potential of integrated experimental-computational methodologies in the field of metallodrugs. These studies have mostly been limited to a few metal-containing systems, such as platinates and vanadium drugs. In this work, we aim to expand and validate the use of combined experimental-theoretical approaches in studying copper (Cu)-based drug interactions with proteins. To do so, a tetracoordinated Cu(II) complex has been employed as a practical case study, and its interactions with several relevant proteins using different experimental and computational techniques have been evaluated, including electron paramagnetic resonance spectroscopy, mass spectrometry, density functional theory, and protein-ligand docking calculations. Experimental data highlight interactions of the Cu(II) complex with albumin, myoglobin, and cytochrome C. Further insights into the preferential modes of binding were evaluated by density functional theory and docking calculations, which revealed three main outer surface binding sites for both albumin and myoglobin, as well as three preferential inner pockets in the case of albumin. The most relevant binding modes found for both proteins include noncoordinative interactions with the Cu(II) dimeric structure intact upon binding, as well as metal-ligand exchange and direct metal-amino acid coordination, mainly to glutamate/aspartate residues after cleavage of the dimer. Altogether, an example of the applicability of a mixed experimental-theoretical framework in the study of Cu-based drug interactions with relevant proteins is shown.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization, Recombinant Production and Structure-Function Analysis of NvCI, A Picomolar Metallocarboxypeptidase Inhibitor from the Marine Snail Nerita versicolor

  • Covaleda Cortés, Giovanni|||0000-0002-7621-852X
  • Hernández, Martha
  • Trejo, Sebastián A.|||0000-0003-2866-5613
  • Mansur, Manuel
  • Rodriguez-Calado, Sergi|||0000-0002-8849-1101
  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Vendrell Roca, Josep|||0000-0002-9378-4742
  • Chávez Planes, María A.
  • Alonso del Rivero, Maday|||0000-0003-1988-6852
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
A very powerful proteinaceous inhibitor of metallocarboxypeptidases has been isolated from the marine snail Nerita versicolor and characterized in depth. The most abundant of four, very similar isoforms, NvCla, was taken as reference and N-terminally sequenced to obtain a 372-nucleotide band coding for the protein cDNA. The mature protein contains 53 residues and three disulphide bonds. NvCIa and the other isoforms show an exceptionally high inhibitory capacity of around 1.8 pM for human Carboxypeptidase A1 (hCPA1) and for other A-like members of the M14 CPA subfamily, whereas a twofold decrease in inhibitory potency is observed for carboxypeptidase B-like members as hCPB and hTAFIa. A recombinant form, rNvCI, was produced in high yield and HPLC, mass spectrometry and spectroscopic analyses by CD and NMR indicated its homogeneous, compact and thermally resistant nature. Using antibodies raised with rNvCI and histochemical analyses, a preferential distribution of the inhibitor in the surface regions of the animal body was observed, particularly nearby the open entrance of the shell and gut, suggesting its involvement in biological defense mechanisms. The properties of this strong, small and stable inhibitor of metallocarboxypeptidases envisage potentialities for its direct applicability, as well as leading or minimized forms, in biotechnological/biomedical uses.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Substrate specificity and structural modeling of human Carboxypeptidase Z, a unique protease with a Frizzled-like domain

  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Tanco, Sebastián Martín|||0000-0003-2130-4401
  • García Guerrero, María del Carmen|||0000-0001-7651-7629
  • Dasgupta, Sayani
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Fricker, Lloyd D.
Metallocarboxypeptidase Z (CPZ) is a secreted enzyme that is distinguished from all other members of the M14 metallocarboxypeptidase family by the presence of an N-terminal cysteine-rich Frizzled-like (Fz) domain that binds Wnt proteins. Here, we present a comprehensive analysis of the enzymatic properties and substrate specificity of human CPZ. To investigate the enzymatic properties, we employed dansylated peptide substrates. For substrate specificity profiling, we generated two different large peptide libraries and employed isotopic labeling and quantitative mass spectrometry to study the substrate preference of this enzyme. Our findings revealed that CPZ has a strict requirement for substrates with C-terminal Arg or Lys at the P1' position. For the P1 position, CPZ was found to display specificity towards substrates with basic, small hydrophobic, or polar uncharged side chains. Deletion of the Fz domain did not affect CPZ activity as a carboxypeptidase. Finally, we modeled the structure of the Fz and catalytic domains of CPZ. Taken together, these studies provide the molecular elucidation of substrate recognition and specificity of the CPZ catalytic domain, as well as important insights into how the Fz domain binds Wnt proteins to modulate their functions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design, synthesis, structure-activity relationships and X-ray structural studies of novel 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as selective and potent inhibitors of human aldose reductase

  • Crespo, Isidro|||0000-0001-7698-1720
  • Giménez-Dejoz, Joan
  • Porté, Sergio
  • Cousido-Siah, Alexandra
  • Mitschler, André
  • Podjarny, Alberto
  • Pratsinis, Harris
  • Kletsas, Dimitris
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Ruiz, Francesc Xavier|||0000-0002-0457-0030
  • Metwally, Kamel
  • Farrés, Jaume|||0000-0001-9069-3987
Human aldose reductase (AKR1B1, AR) is a key enzyme of the polyol pathway, catalyzing the reduction of glucose to sorbitol at high glucose concentrations, as those found in diabetic condition. Indeed, AKR1B1 overexpression is related to diabetes secondary complications and, in some cases, with cancer. For many years, research has been focused on finding new AKR1B1 inhibitors (ARIs) to overcome these diseases. Despite the efforts, most of the new drug candidates failed because of their poor pharmacokinetic properties and/or unacceptable side effects. Here we report the synthesis of a series of 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as novel ARIs. IC50 assays and X-ray crystallographic studies proved that these compounds are promising hits for further drug development, with high potency and selectivity against AKR1B1. Based on the determined X-ray structures with hit-to-lead compounds, we designed and synthesized a second series that yielded lead compound 68 (Kiapp vs. AKR1B1 = 73 nM). These compounds are related to the previously reported 2-aminopyrimido[4,5-c]quinolin-1(2H)-ones, which exhibit antimitotic activity. Regardless of their similarity, the 2-amino compounds are unable to inhibit AKR1B1 while the 2-acetic acid derivatives are not cytotoxic against fibrosarcoma HT-1080 cells. Thus, the replacement of the amino group by an acetic acid moiety changes their biological activity, improving their potency as ARIs.